The NICE QOF advisory committee has decided to pilot indicators for osteoporosis and fractures with a view to inclusion in the 2012/2013 framework; a six-monthly injectable anti-resorptive agent recently launched in the UK is to be incorporated into NOGG guidance; and NICE will review the need to update its 2008 technology appraisals for the primary and secondary prevention of osteoporotic fragility fractures in postmenopausal women.